BPC-157 vs Growth Hormone
Side-by-Side Comparison
| Attribute | Bpc 157 | Growth Hormone |
|---|---|---|
| Category | Healing & Recovery | Hormone |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Growth hormone binds to the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling pathway. |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | FDA-approved for multiple indications. First approved in 1985 (recombinant form). |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia); Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Subcutaneous |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | Adults: 0.15–0.3 mg/day SC (GH deficiency); Pediatric: 0.025–0.05 mg/kg/day SC |
| Frequency | Once daily | Once daily (typically evening) |
| Molecular Weight | ~1419.5 g/mol | ~22,124 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~20-30 min (endogenous IV); SC injection effective duration ~12-16 hours |
Overview
BPC-157 and Growth Hormone are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Growth Hormone — Mechanism & Evidence
Human growth hormone (hGH, somatotropin) is a 191-amino acid protein produced by the anterior pituitary gland. Recombinant human growth hormone (rhGH, somatropin) is FDA-approved for numerous indications including pediatric and adult growth hormone deficiency, Turner syndrome, short stature from small for gestational age (SGA), Prader-Willi syndrome, chronic kidney disease, idiopathic short stature, and short bowel syndrome (Zorbtive). It is one of the most extensively studied hormones in medicine. Off-label use for anti-aging and performance enhancement is widespread but not approved, and GH is banned by WADA in sport.
Key claims: Treats growth hormone deficiency in children; Treats adult growth hormone deficiency; Anti-aging effects.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Growth Hormone targets GH Deficiency Treatment, Pediatric Growth Disorders, Reference.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Growth Hormone: Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia) Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes Fluid retention: peripheral edema, especially at treatment initiation
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
Anti-Aging Peptides: Research Compounds for Metabolism, Muscle, and Tissue Health
Explore a curated selection of anti-aging research peptides including BPC-157, GHK-CU, KPV, MOTS-C, NAD+, Retatrutide, SS-31, TB-500, and others. These compounds are studied for their potential roles in metabolism support, muscle growth, weight loss, and skin, tissue, and bone health. Average purity across products is 99.77%.